Breaking News Instant updates and real-time market news.

DISH

Dish

$17.99 /

-0.46 (-2.49%)

 11:35
07/06/22
 07/06
11:35
 07/06/22
11:35

Dish Network put volume heavy and directionally bearish

Bearish flow noted in Dish Network with 13,920 puts trading, or 4x expected. Most active are 7/8 weekly 18 puts and 7/8 weekly 16 puts, with total volume in those strikes near 10,100 contracts. The Put/Call Ratio is 52.73, while ATM IV is up over 4 points on the day. Earnings are expected on August 4th.

OTHER BREAKING NEWS FROM THE FLY

Earnings
Gencor Industries reports Q3 EPS (7c) vs. 16c last year » 07:12
08/12/22
08/12
07:12
08/12/22
07:12
GENC

Gencor Industries

$9.57 /

-0.08 (-0.83%)

Reports Q3 revenue $29.6M…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GENC Gencor Industries
$9.57 /

-0.08 (-0.83%)

07/19/22
Gencor Industries transfers common stock listing to NYSE American
GENC Gencor Industries
$9.57 /

-0.08 (-0.83%)

05/13/22
Gencor Industries reports Q2 EPS 3c vs 16c last year
Recommendations
Chicken Soup for the Soul price target raised to $52 from $40 at DA Davidson » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
CSSE

Chicken Soup for the Soul

/

+

, RDBX

Redbox

$1.71 /

+ (+0.00%)

, ROKU

Roku

$80.65 /

-0.33 (-0.41%)

DA Davidson analyst Tom…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CSSE Chicken Soup for the Soul
/

+

08/11/22
Chicken Soup for the Soul reports Q2 adjusted EBITDA $5.6M vs. $3.2M y/y
08/10/22
Nasdaq says Redbox trading to be halted following after-hours session on Aug. 10
08/09/22
Redbox's stockholders approve merger proposal with Chicken Soup for the Soul
07/14/22
Crackle, Popcornflix FAST channels launch on FuboTV
RDBX Redbox
$1.71 /

+ (+0.00%)

08/10/22
Nasdaq says Redbox trading to be halted following after-hours session on Aug. 10
08/09/22
Redbox's stockholders approve merger proposal with Chicken Soup for the Soul
06/14/22
Redbox down 22.5% in pre-market trading, remains most active on Stocktwits
06/13/22
Redbox up another 19% amid increase in StockTwits message volume
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/03/22
Paramount+ to launch as a Premium Subscription within Roku Channel
07/28/22
Roku drops 25% to $63.40 after Q2 results, Q3 guidance miss estimates
07/26/22
Cathie Wood's ARK Investment bought 585K shares of Roku today
06/23/22
Crackle launches updated app on Roku devices
CSSE Chicken Soup for the Soul
/

+

07/12/22 B. Riley
Chicken Soup sees positive free cash flow by year-end, says B. Riley
06/14/22 DA Davidson
DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal
05/27/22 B. Riley
Redbox downgraded to Sell from Neutral at B. Riley
05/17/22 Guggenheim
Chicken Soup for the Soul resumed with a Buy at Guggenheim
RDBX Redbox
$1.71 /

+ (+0.00%)

07/12/22 B. Riley
Chicken Soup sees positive free cash flow by year-end, says B. Riley
06/14/22 DA Davidson
DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal
05/27/22 B. Riley
Redbox downgraded to Sell from Neutral at B. Riley
05/17/22 Guggenheim
Chicken Soup for the Soul resumed with a Buy at Guggenheim
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/10/22 MoffettNathanson
MoffettNathanson downgrades Roku to sell on 'challenged' position
08/10/22 MoffettNathanson
Roku downgraded to Underperform from Market Perform at MoffettNathanson
08/08/22 Pivotal Research
Roku downgraded to Sell from Hold at Pivotal Research
08/03/22 Citi
Roku price target lowered to $125 from $165 at Citi
CSSE Chicken Soup for the Soul
/

+

08/11/22
Chicken Soup for the Soul reports Q2 EPS ($1.39), consensus (72c)
05/11/22
Chicken Soup for the Soul reports Q1 adjusted EPS (83c), consensus (71c)
03/31/22
Chicken Soup for the Soul reports Q4 EPS ($1.38), consensus (51c)
ROKU Roku
$80.65 /

-0.33 (-0.41%)

07/28/22
Roku sees Q3 revenue roughly $700M, consensus $901.73M
07/28/22
Roku reports Q2 EPS (82c), consensus (68c)
07/28/22
Notable companies reporting after market close
04/28/22
Roku backs FY22 revenue growth view of 35% y/y, consensus $3.72B
ROKU Roku
$80.65 /

-0.33 (-0.41%)

06/14/22
Netflix talked with Roku, Comcast about ad sales, The Information reports
06/08/22
Roku staff 'buzzing' about possibility of being bought by Netflix, Insider says
05/06/22
Microsoft working on Xbox Cloud streaming device for TVs, VentureBeat says
05/03/22
Roku, Apollo team to bid for minority stake in Starz, WSJ reports
CSSE Chicken Soup for the Soul
/

+

08/11/22
Fly Intel: After-Hours Movers
05/11/22
What You Missed On Wall Street On Wednesday
05/11/22
What You Missed On Wall Street This Morning
RDBX Redbox
$1.71 /

+ (+0.00%)

08/07/22
Short Report: Bed Bath Beyond in short-squeeze spotlight
08/01/22
Short Report: Bets against Beyond Meat pared as McPlant test ends
07/16/22
Short Report: Canoo shorts going along for the ride
07/09/22
Short Report: Carvana, Bed Bath Beyond short interest continues to grow
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/10/22
What You Missed On Wall Street On Wednesday
08/10/22
What You Missed On Wall Street This Morning
08/10/22
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
08/08/22
What You Missed On Wall Street On Monday
09/08/22
Consumer/Media/Entertainment Conference
09/12/22
Chicken Soup for the Soul - CSSE
09/08/22
Roku
CSSE Chicken Soup for the Soul
/

+

08/11/22
Chicken Soup for the Soul Entertainment options imply 14.7% move in share price post-earnings
08/03/22
Largest borrow rate increases among liquid names
07/15/22
Largest borrow rate increases among liquid names
07/01/22
Largest borrow rate increases among liquid names
RDBX Redbox
$1.71 /

+ (+0.00%)

06/15/22
Unusually active option classes on open June 15th
06/10/22
Redbox Entertainment Inc call volume above normal and directionally bullish
06/08/22
Unusually active option classes on open June 8th
06/07/22
Redbox Entertainment Inc call volume above normal and directionally bullish
ROKU Roku
$80.65 /

-0.33 (-0.41%)

08/02/22
Roku call volume above normal and directionally bullish
08/01/22
Unusually active option classes on open August 1st
07/28/22
Roku options imply 10.5% move in share price post-earnings
06/08/22
Unusually active option classes on open June 8th
Downgrade
Allegiant Travel downgraded to Peer Perform from Outperform at Wolfe Research » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
ALGT

Allegiant Travel

$107.03 /

-0.12 (-0.11%)

Wolfe Research analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

07/25/22
Allegiant Travel reports June traffic up 9.2%
06/22/22
Allegiant Travel becomes official airline of Detroit Pistons
06/17/22
Allegiant Travel reports preliminary May traffic up 47.3% y/y
06/17/22
Allegiant Travel reports preliminary May traffic up 19.7% vs. 2019
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

07:00 Today Wolfe Research
Allegiant Travel downgraded to Peer Perform from Outperform at Wolfe Research
08/10/22 Barclays
Allegiant Travel price target lowered to $150 from $180 at Barclays
08/04/22 Deutsche Bank
Allegiant Travel price target lowered to $190 from $245 at Deutsche Bank
07/26/22 Susquehanna
Allegiant Travel negative reveal suggests price sensitivity, says Susquehanna
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

08/03/22
Allegiant Travel sees Q3 revenue up 29% year over three-year, consensus $589.67M
08/03/22
Allegiant Travel reports Q2 adjusted EPS 62c, consensus 92c
07/25/22
Allegiant Travel sees Q2 EPS 62c, consensus $1.38
07/25/22
Allegiant Travel sees Q2 revenue $629M, consensus $632.4M
ALGT Allegiant Travel
$107.03 /

-0.12 (-0.11%)

07/25/22
Fly Intel: After-Hours Movers
Hot Stocks
HCW Biologics expects cash to fund operations through end of 2023 » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
HCWB

HCW Biologics

$2.04 /

-0.21 (-9.33%)

On June 30, 2022, the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

08/03/22
HCW Biologics announces US issued patent for platform technology
05/13/22
HCW Biologics expects cash to fund operations until end of 2023
05/05/22
HCW Biologics to present two groups of novel immunotherapeutics
04/19/22
HCW Biologics CEO to be featured speaker at CEB-2022
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

07:10 Today
HCW Biologics reports Q2 EPS (66c) vs (10c) last year
05/13/22
HCW Biologics reports Q1 EPS (6c) vs (69c) last year
03/28/22
HCW Biologics reports Q4 net loss $3.2M vs $2.1M last year
Earnings
HCW Biologics reports Q2 EPS (66c) vs (10c) last year » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
HCWB

HCW Biologics

$2.04 /

-0.21 (-9.33%)

Reports Q2 revenue $0 vs…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

08/03/22
HCW Biologics announces US issued patent for platform technology
05/13/22
HCW Biologics expects cash to fund operations until end of 2023
05/05/22
HCW Biologics to present two groups of novel immunotherapeutics
04/19/22
HCW Biologics CEO to be featured speaker at CEB-2022
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
03/24/22 Maxim
HCW Biologics initiated with a Buy at Maxim
HCWB HCW Biologics
$2.04 /

-0.21 (-9.33%)

05/13/22
HCW Biologics reports Q1 EPS (6c) vs (69c) last year
03/28/22
HCW Biologics reports Q4 net loss $3.2M vs $2.1M last year
Earnings
Silver Spike Investment reports Q1 NII 4c vs. ($425.03) last year » 07:10
08/12/22
08/12
07:10
08/12/22
07:10
SSIC

Silver Spike Investment

$8.86 /

-0.33 (-3.59%)

Net asset value per share…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SSIC Silver Spike Investment
$8.86 /

-0.33 (-3.59%)

03/01/22 Piper Sandler
Silver Spike Investment initiated with an Overweight at Piper Sandler
03/01/22 Stifel
Silver Spike Investment initiated with a Hold at Stifel
  • 04
    Feb
Earnings
Instil Bio reports Q2 adjusted EPS (40c), consensus (41c) » 07:08
08/12/22
08/12
07:08
08/12/22
07:08
TIL

Instil Bio

$6.79 /

+0.09 (+1.34%)

As of June 30, 2022, we…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

05/27/22
Instill Bio Inc trading resumes
05/27/22
Instill Bio Inc trading halted, volatility trading pause
05/27/22
Instil Bio announces IND clearance of ITIL-306
05/18/22
Instil Bio to present novel TIL analytics at ASGCT
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

06/05/22 Morgan Stanley
Instil Bio price target lowered to $9 from $14 at Morgan Stanley
08/13/21 Baird
Baird sees likely success for Instil Bio lead candidate, starts at Outperform
08/12/21 Baird
Instil Bio initiated with an Outperform at Baird
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

05/16/22
Instil Bio reports Q1 EPS (42c), consensus (38c)
03/07/22
Instil Bio reports Q4 EPS (43c), consensus (36c)
TIL Instil Bio
$6.79 /

+0.09 (+1.34%)

03/30/22
Four new option listings and one option delisting on March 30th
Hot Stocks
Rapid Micro Biosystems adopts stockholder rights plan » 07:08
08/12/22
08/12
07:08
08/12/22
07:08
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Rapid Micro Biosystems…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:07 Today
Rapid Micro Biosystems announces review of strategic alternatives
07:06 Today
Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis
07:05 Today
Rapid Micro Biosystems CCO Andy Keys departs
07:05 Today
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:03 Today
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M
07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
08:30 Today
Rapid Micro Biosystems - RPID
Hot Stocks
Rapid Micro Biosystems announces review of strategic alternatives » 07:07
08/12/22
08/12
07:07
08/12/22
07:07
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Rapid Micro Biosystems…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:06 Today
Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis
07:05 Today
Rapid Micro Biosystems CCO Andy Keys departs
07:05 Today
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction
06/30/22
Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:03 Today
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M
07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
08:30 Today
Rapid Micro Biosystems - RPID
Recommendations
Marriott Vacations price target lowered to $202 from $205 at Truist » 07:07
08/12/22
08/12
07:07
08/12/22
07:07
VAC

Marriott Vacations

$146.63 /

+1.64 (+1.13%)

Truist analyst Patrick…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VAC Marriott Vacations
$146.63 /

+1.64 (+1.13%)

08/01/22
Marriott Vacations raises share repurchase authorization by $500M
06/16/22
Marriott Vacations raises 2022 contract sales guidance by $100M
06/09/22
Marriott Vacations CEO Stephen Weisz to retire, John Geller, Jr to succeed
02/23/22
Marriott Vacations sees FY22 contract sales up 13% vs. 2019
VAC Marriott Vacations
$146.63 /

+1.64 (+1.13%)

08/10/22 Barclays
Marriott Vacations price target raised to $165 from $136 at Barclays
08/10/22 Deutsche Bank
Marriott Vacations price target raised to $192 from $188 at Deutsche Bank
06/28/22 Barclays
Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names
06/28/22 Barclays
Marriott Vacations initiated with an Overweight at Barclays
VAC Marriott Vacations
$146.63 /

+1.64 (+1.13%)

08/08/22
Marriott Vacations sees FY22 adjusted EPS $9.47-$10.35, consensus $9.49
08/08/22
Marriott Vacations reports Q2 adjusted EPS $2.87, consensus $2.27
05/05/22
Marriott Vacations sees FY22 adjusted EPS $9.13-$10.09, consensus $9.22
05/05/22
Marriott Vacations reports Q1 adjusted EPS $1.70, consensus $1.53
Recommendations
Travel + Leisure price target lowered to $72 from $78 at Truist » 07:07
08/12/22
08/12
07:07
08/12/22
07:07
TNL

Travel + Leisure

$45.78 /

+0.795 (+1.77%)

Truist analyst C. Patrick…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TNL Travel + Leisure
$45.78 /

+0.795 (+1.77%)

04/28/22
Travel + Leisure board approves $500M increase to share repurchase plan
03/02/22
Travel + Leisure increases quarterly cash dividend 5c to 40c per share
TNL Travel + Leisure
$45.78 /

+0.795 (+1.77%)

08/01/22 Deutsche Bank
Travel + Leisure price target lowered to $69 from $76 at Deutsche Bank
07/28/22 Stifel
Travel + Leisure price target lowered to $61 from $76 at Stifel
06/28/22 Barclays
Travel + Leisure initiated with an Equal Weight at Barclays
04/29/22 Jefferies
Travel + Leisure upgraded to Buy at Jefferies after positive headline results
TNL Travel + Leisure
$45.78 /

+0.795 (+1.77%)

07/28/22
Travel + Leisure sees FY22 adjusted EBITDA $860M-$880M
07/28/22
Travel + Leisure sees Q3 adjusted EBITDA $230M-$240M
07/28/22
Travel + Leisure reports Q2 adjusted EPS $1.27, consensus $1.19
04/28/22
Travel + Leisure sees FY22 adjusted EBITDA $855M-$875M
Recommendations
Hilton Grand Vacations price target lowered to $63 from $64 at Truist » 07:07
08/12/22
08/12
07:07
08/12/22
07:07
HGV

Hilton Grand Vacations

$43.49 /

-0.17 (-0.39%)

Truist analyst C. Patrick…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HGV Hilton Grand Vacations
$43.49 /

-0.17 (-0.39%)

05/09/22
Hilton Grand Vacations sees 2022 Deferral Adjusted EBITDA $600M-$990M
05/09/22
Hilton Grand Vacations board approves $500M share repurchase program
05/09/22
Hilton Grand Vacations expects cost synergies of $150M from Diamond transaction
HGV Hilton Grand Vacations
$43.49 /

-0.17 (-0.39%)

06/28/22 Barclays
Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names
06/28/22 Barclays
Hilton Grand Vacations initiated with an Overweight at Barclays
03/08/22 Truist
Hilton Grand Vacations price target raised to $63 from $60 at Truist
12/06/21 Truist
Hilton Grand Vacations price target raised to $60 from $54 at Truist
HGV Hilton Grand Vacations
$43.49 /

-0.17 (-0.39%)

08/09/22
Hilton Grand Vacations backs FY22 adjusted EBITDA view $960M-$990M
08/09/22
Hilton Grand Vacations reports Q2 EPS with-items 60c, consensus 88c
05/09/22
Hilton Grand Vacations reports Q1 EPS 42c, consensus 64c
03/01/22
Hilton Grand Vacations reports Q4 EPS 62c, one estimate 88c
09/22/22
Hilton Grand Vacations - HGV
Earnings
Applied Therapeutics reports Q2 EPS (96c), consensus (78c) » 07:06
08/12/22
08/12
07:06
08/12/22
07:06
APLT

Applied Therapeutics

$1.31 /

+0.09 (+7.38%)

Cash and cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

06/03/22
Applied receives orphan medicinal product designation from EMA for AT-007
02/28/22
Applied Therapeutics supports annual Rare Disease Day
APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

05/12/22
Applied Therapeutics reports Q1 EPS (88c), consensus (83c)
03/10/22
Applied Therapeutics reports FY21 EPS ($4.12), consensus ($4.38)
  • 23
    Jun
APLT Applied Therapeutics
$1.31 /

+0.09 (+7.38%)

06/22/22
Fly Intel: After-Hours Movers
Recommendations
Bluegreen Vacations price target lowered to $56 from $57 at Truist » 07:06
08/12/22
08/12
07:06
08/12/22
07:06
BVH

Bluegreen Vacations

$23.67 /

+0.01 (+0.04%)

Truist analyst C. Patrick…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BVH Bluegreen Vacations
$23.67 /

+0.01 (+0.04%)

03/03/22
Bluegreen Vacations authorizes additional $50M share repurchase program
BVH Bluegreen Vacations
$23.67 /

+0.01 (+0.04%)

03/08/22 Truist
Bluegreen Vacations price target raised to $56 from $44 at Truist
11/16/21 Truist
Bluegreen Vacations price target raised to $44 from $41 at Truist
11/05/21 B. Riley
Bluegreen Vacations price target raised to $59 from $42.50 at B. Riley
09/29/21 Truist
Bluegreen Vacations Holding assumed with a Buy at Truist
BVH Bluegreen Vacations
$23.67 /

+0.01 (+0.04%)

03/03/22
Bluegreen Vacations reports Q4 cont-op EPS 59c, consensus 62c
Hot Stocks
Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis » 07:06
08/12/22
08/12
07:06
08/12/22
07:06
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

In addition, the Company…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:05 Today
Rapid Micro Biosystems CCO Andy Keys departs
07:05 Today
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction
06/30/22
Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis
06/30/22
Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:03 Today
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M
07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
08:30 Today
Rapid Micro Biosystems - RPID
Downgrade
TIS Inc. downgraded to Neutral from Buy at Citi » 07:06
08/12/22
08/12
07:06
08/12/22
07:06
TISNF

TIS Inc.

/

+

Citi analyst Mitsunobu…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TISNF TIS Inc.
/

+

05/26/22 Jefferies
TIS Inc. downgraded to Hold from Buy at Jefferies
12/14/21 Daiwa
TIS Inc. upgraded to Outperform from Neutral at Daiwa
10/01/21 Credit Suisse
TIS Inc. downgraded to Neutral from Outperform at Credit Suisse
09/17/21 Daiwa
TIS Inc. downgraded to Neutral from Outperform at Daiwa
Recommendations
System1 price target lowered to $13 from $15 at Benchmark » 07:06
08/12/22
08/12
07:06
08/12/22
07:06
SST

System1

$8.69 /

+0.045 (+0.52%)

Benchmark analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SST System1
$8.69 /

+0.045 (+0.52%)

06/07/22
System1 set to join Russell 2000, Russell 3000 Indexes
05/13/22
Starboard takes stake in Humana, exits System1
04/19/22
System1 falls -33.8%
04/19/22
System1 falls -28.6%
SST System1
$8.69 /

+0.045 (+0.52%)

07/11/22 BofA
BofA starts System1 at Buy with $12 price target
07/11/22 BofA
System1 initiated with a Buy at BofA
04/26/22 Evercore ISI
System1 initiated with an In Line at Evercore ISI
04/06/22 DA Davidson
System1 price target raised to $26 from $23 at DA Davidson
SST System1
$8.69 /

+0.045 (+0.52%)

08/11/22
System1 sees FY22 revenue $900M-$930M, consensus $997.34M
08/11/22
System1 reports Q2 revenue $220M, consensus $218.82M
04/04/22
System1 sees FY22 revenue $1B
04/04/22
System1 reports Q4 revenue $238.9M vs. $160.9M last year
SST System1
$8.69 /

+0.045 (+0.52%)

08/11/22
Fly Intel: After-Hours Movers
05/20/22
Proven algorithm says sell these stocks now
04/19/22
What You Missed On Wall Street This Morning
04/18/22
Fly Intel: After-Hours Movers
09/08/22
Consumer/Media/Entertainment Conference
SST System1
$8.69 /

+0.045 (+0.52%)

08/11/22
System1 options imply 10.1% move in share price post-earnings
07/29/22
Largest borrow rate increases among liquid names
07/22/22
Largest borrow rate increases among liquid names
07/21/22
Largest borrow rate increases among liquid names
Hot Stocks
Iterum Therapeutics expects cash to fund operations into 2024 » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
ITRM

Iterum Therapeutics

$0.25 /

+0.0007 (+0.28%)

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ITRM Iterum Therapeutics
$0.25 /

+0.0007 (+0.28%)

07/11/22
Iterum announces SPA agreement with FDA on Phase 3 trial of oral sulopenem
05/13/22
Iterum Therapeutics sees cash, equivalents funding operations into 2024
05/11/22
Iterum reaches 'general alignment' with FDA on aspects of Phase 3 trial design
03/28/22
Iterum Therapeutics sees cash, cash equivalents funding operations into 2024
ITRM Iterum Therapeutics
$0.25 /

+0.0007 (+0.28%)

07:05 Today
Iterum Therapeutics reports Q2 adjusted EPS (3c) vs (4c) last year
05/13/22
Iterum Therapeutics reports Q1 adjusted EPS (3c) vs. (5c) last year
03/28/22
Iterum Therapeutics reports Q4 adjusted EPS (2c) vs. (11c) last year
Earnings
Iterum Therapeutics reports Q2 adjusted EPS (3c) vs (4c) last year » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
ITRM

Iterum Therapeutics

$0.25 /

+0.0007 (+0.28%)

"We are excited to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ITRM Iterum Therapeutics
$0.25 /

+0.0007 (+0.28%)

07/11/22
Iterum announces SPA agreement with FDA on Phase 3 trial of oral sulopenem
05/13/22
Iterum Therapeutics sees cash, equivalents funding operations into 2024
05/11/22
Iterum reaches 'general alignment' with FDA on aspects of Phase 3 trial design
03/28/22
Iterum Therapeutics sees cash, cash equivalents funding operations into 2024
ITRM Iterum Therapeutics
$0.25 /

+0.0007 (+0.28%)

05/13/22
Iterum Therapeutics reports Q1 adjusted EPS (3c) vs. (5c) last year
03/28/22
Iterum Therapeutics reports Q4 adjusted EPS (2c) vs. (11c) last year
Earnings
Casi Pharmaceuticals reports Q2 EPS (56c), consensus (64c) » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
CASI

Casi Pharmaceuticals

$3.91 /

+0.91 (+30.33%)

Reports Q2 revenue $8.6M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CASI Casi Pharmaceuticals
$3.91 /

+0.91 (+30.33%)

07/08/22
Casi announces Precision Autoimmune completed first-round financing of $21M
05/26/22
Casi Pharmaceuticals announces 1-for-10 reverse stock split
05/24/22
Casi signs sublicense agreement with Beijing Tianshi Tongda for anti-CD38
04/01/22
Casi Pharmaceuticals issues statement on status under HFCAA
CASI Casi Pharmaceuticals
$3.91 /

+0.91 (+30.33%)

06/03/22 BTIG
Casi Pharmaceuticals price target adjusted to $21 at BTIG after 1 for 10 split
05/26/22 Oppenheimer
Casi Pharmaceuticals should benefit from Shanghai's reopening, says Oppenheimer
05/13/22 H.C. Wainwright
Casi Pharmaceuticals price target lowered to $3 from $4 at H.C. Wainwright
CASI Casi Pharmaceuticals
$3.91 /

+0.91 (+30.33%)

05/12/22
Casi Pharmaceuticals reports Q1 EPS (6c), consensus (9c)
02/16/22
Casi Pharmaceuticals sees FY22 revenue growth 30%, consensus $39.75M
02/16/22
Casi Pharmaceuticals sees Q4 revenue $9.12M, consensus $8.5M
08:00 Today
Casi Pharmaceuticals - CASI
Hot Stocks
Rapid Micro Biosystems CCO Andy Keys departs » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

In connection with the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:05 Today
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction
06/30/22
Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis
06/30/22
Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:03 Today
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M
07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
08:30 Today
Rapid Micro Biosystems - RPID
Earnings
Fennec reports Q2 EPS (19c), consensus (14c) » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
FENC

Fennec

$6.99 /

+0.07 (+1.01%)

Cash and cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FENC Fennec
$6.99 /

+0.07 (+1.01%)

08/01/22
Fennec announces up to $45M investment from Petrichor
04/27/22
Fennec announces FDA approval of NDA resubmission for PEDMARK
03/24/22
Fennec resubmits NDA to FDA for Pedmark
02/28/22
Fennec expects cash to fund activities for 2022
FENC Fennec
$6.99 /

+0.07 (+1.01%)

08/08/22 Craig-Hallum
Fennec assumed with a Buy at Craig-Hallum
12/01/21 Maxim
Fennec price target lowered to $10 from $12 at Maxim
11/30/21 Craig-Hallum
Fennec price target lowered to $14 from $19 at Craig-Hallum
FENC Fennec
$6.99 /

+0.07 (+1.01%)

02/28/22
Fennec reports Q4 EPS (18c), consensus 75c
09/23/22
PDUFA Date for Pedmark
Hot Stocks
Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction » 07:05
08/12/22
08/12
07:05
08/12/22
07:05
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

The Company is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

06/30/22
Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis
06/30/22
Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:03 Today
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M
07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
08:30 Today
Rapid Micro Biosystems - RPID
Earnings
Leap Therapeutics reports Q2 EPS (15c), consensus (10c) » 07:04
08/12/22
08/12
07:04
08/12/22
07:04
LPTX

Leap Therapeutics

$1.32 /

+0.15 (+12.82%)

Cash and cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

07/12/22
Leap Therapeutics and BeiGene begin Part C of the DisTinGuish study
05/26/22
Leap Therapeutics presents initial Phase 1b/2 data of DKN-01 in prostate cancer
LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

06/06/22 Piper Sandler
Piper says Leap's DKN-01 combo showed 'interesting early signal of activity'
05/27/22 Piper Sandler
Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler
01/23/22 Piper Sandler
Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
LPTX Leap Therapeutics
$1.32 /

+0.15 (+12.82%)

05/13/22
Leap Therapeutics reports Q1 EPS (9c), consensus (10c)
03/11/22
Leap Therapeutics reports Q4 EPS (10c), consensus (11c)
  • 22
    Sep
Earnings
Rapid Micro Biosystems lowers FY22 revenue view to at least $17M » 07:03
08/12/22
08/12
07:03
08/12/22
07:03
RPID

Rapid Micro Biosystems

$4.21 /

-0.03 (-0.71%)

Consensus $28.01M. The…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

06/30/22
Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis
06/30/22
Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

10/14/21 Cowen
Rapid Micro Biosystems coverage transferred at Cowen
RPID Rapid Micro Biosystems
$4.21 /

-0.03 (-0.71%)

07:02 Today
Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year
05/10/22
Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M
05/10/22
Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c)
03/04/22
Rapid Micro Biosystems backs FY22 commercial revenue view $27M-$32M
08:30 Today
Rapid Micro Biosystems - RPID

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.